Zhitong Financial App News, Dizhe Pharmaceutical (688192.SH) announced that at the 68th American Society of Hematology (ASH) Annual Meeting to be held in New Orleans, USA from December 12 to 15, the company will announce the 8 latest clinical research results of the hematologic tumor pipeline, including 3 oral reports and 5 poster presentations, involving the company's three core products in the field of hematoma - the highly selective JAK1 inhibitor Collixitinib® (golixitinib), and the new generation EZH1/ 2 dual-target small molecule inhibitors GW5282. Among them, Collegel® and biritinib received oral reports, and GW5282 clinical study data on relapsed/refractory non-Hodgkin lymphoma (r/r NHL) will also be published for the first time.

Zhitongcaijing · 1d ago
Zhitong Financial App News, Dizhe Pharmaceutical (688192.SH) announced that at the 68th American Society of Hematology (ASH) Annual Meeting to be held in New Orleans, USA from December 12 to 15, the company will announce the 8 latest clinical research results of the hematologic tumor pipeline, including 3 oral reports and 5 poster presentations, involving the company's three core products in the field of hematoma - the highly selective JAK1 inhibitor Collixitinib® (golixitinib), and the new generation EZH1/ 2 dual-target small molecule inhibitors GW5282. Among them, Collegel® and biritinib received oral reports, and GW5282 clinical study data on relapsed/refractory non-Hodgkin lymphoma (r/r NHL) will also be published for the first time.